Conatus Pharmaceuticals (Conatus Pharmaceuticals) EV-to-Revenue : 1.26 (As of Apr. 26, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Conatus Pharmaceuticals's enterprise value is $18.44 Mil. Conatus Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2020 was $14.69 Mil. Therefore, Conatus Pharmaceuticals's EV-to-Revenue for today is 1.26.

The historical rank and industry rank for Conatus Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

CNAT's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.68
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Conatus Pharmaceuticals's stock price is $0.56. Conatus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2020 was $0.44. Therefore, Conatus Pharmaceuticals's PS Ratio for today is 1.26.

Conatus Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Conatus Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conatus Pharmaceuticals EV-to-Revenue Chart

Conatus Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EV-to-Revenue

Get a 7-Day Free Trial

77.13

2.18

0.50

-0.33

Conatus Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
EV-to-Revenue	Get a 7-Day Free Trial															0.08	-0.60	-0.41	-0.33	-0.51

Competitive Comparison of Conatus Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Conatus Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Conatus Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conatus Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Conatus Pharmaceuticals's EV-to-Revenue falls into.

Conatus Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Conatus Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	18.443	/	14.693
	=	1.26

Conatus Pharmaceuticals's current Enterprise Value is $18.44 Mil.
Conatus Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.69 Mil.

Conatus Pharmaceuticals (NAS:CNAT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Conatus Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.56	/	0.443
	=	1.26

Conatus Pharmaceuticals's share price for today is $0.56.
Conatus Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.44.

Conatus Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127

Website

https://www.conatuspharma.com

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.